Home / Industry / Pharmaceuticals & Biotechnology / Lung Cancer Surgery Market

Lung Cancer Surgery Market

Lung Cancer Surgery Market Insights, Competitive Landscape, and Market Forecast - 2033

Published Date: Jul 2026 | Format: | No. of Pages: 188

Industry: Pharmaceuticals & Biotechnology | Author Name: Sayali

Request Customisation / Information

  
$4,995.00
Buy now
Report Description Research Methodology

FAQ : Lung Cancer Surgery Market

The global lung cancer surgery market is valued at US$ 5.40 Billion in 2026 and is projected to reach US$ 6.69 Billion by 2033, growing at a CAGR of 3.1%.

Market growth is driven by expanding low-dose CT screening programs and increasing adoption of minimally invasive and sublobar surgical procedures for early-stage lung cancer.

Lobectomy leads the market with a 52.8% share as it remains the standard surgical treatment for resectable stage I–II NSCLC patients.

North America dominates with a 35.2% market share due to advanced surgical infrastructure, favorable reimbursement policies, and widespread adoption of robotic and VATS technologies.

The biggest opportunity lies in expanding segmentectomy and sublobar resection programs alongside growing surgical capacity investments in emerging markets such as China and India.
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services